Patients
26.0 % of adults
Obesity (adults), Canada, 2024 (WHO).
Compare every country on the Public Health Dashboard
Updated
Reviewed by Vidhi Upadhyay
Canada Endoscopic Bariatric Therapies Market Industry Trends and Forecast to 2034: Segmented by (Procedure, Product, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$120.7 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $58.4 Mn | — | — |
| 2025 (base) | $65.6 Mn | +$7.2 Mn | — |
| 2026 (forecast) | $73.6 Mn | +$8.1 Mn | +12.3% |
| 2027 (forecast) | $82.7 Mn | +$9.1 Mn | +26.1% |
| 2028 (forecast) | $92.9 Mn | +$10.2 Mn | +41.6% |
| 2029 (forecast) | $104.3 Mn | +$11.4 Mn | +59% |
| 2030 (forecast) | $117.1 Mn | +$12.8 Mn | +78.6% |
| 2031 (forecast) | $131.5 Mn | +$14.4 Mn | +100.6% |
| 2032 (forecast) | $147.7 Mn | +$16.2 Mn | +125.2% |
| 2033 (forecast) | $165.9 Mn | +$18.2 Mn | +153% |
| 2034 (forecast) | $186.3 Mn | +$20.4 Mn | +184.1% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $65.6 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $186.3 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 12.3% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Procedure, product and end user (see all) |
| Key players | Boston Scientific Corporation, Apollo Endosurgery, Fractyl Health, GI Dynamics, Olympus Corporation (see all) |
| Regulator in Canada | Health CanadaSource: Health Canada. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Endoscopic bariatric therapies are weight-loss procedures done through the mouth with a flexible scope, without cuts in the skin.
Key segments of the endoscopic Bariatric Therapies market include procedure (Endoscopic Sleeve Gastroplasty, Intragastric Balloon and Duodenal Mucosal Resurfacing) and product (Suturing Systems, Balloons and Liners).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the endoscopic Bariatric Therapies market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the endoscopic Bariatric Therapies market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the endoscopic Bariatric Therapies market. Long-term safety data and lifestyle support are still needed for many patients.
The endoscopic Bariatric Therapies market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Health Canada licenses Class II, III and IV medical devices; Class I devices are sold by companies that hold an establishment licence.[1] Each province and territory runs public health insurance under the Canada Health Act, which covers medically necessary hospital and doctor services.[2] Obesity (adults): 26.0% of adults in 2024, the latest WHO figure for Canada.[3]
[1] Health Canada. Checked 14 Nov 2026.
[2] Health Canada. Checked 14 Nov 2026.
[3] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 20 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how endoscopic Bariatric Therapies products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Canada.
What doctors and scientists are doing in Endoscopic Bariatric Therapies right now, from free public sources.
26.0 % of adults
Obesity (adults), Canada, 2024 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 19 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.
From our blog
Canada · 1 shared keyword
Canada · 1 shared keyword
Canada · 1 shared keyword
Canada
Canada
Canada
Pharmaceuticals · Canada
Pharmaceuticals · Canada
Healthcare Services · Canada
Digital Health · Canada
Pharmaceuticals · Canada
Pharmaceuticals · Canada